357 Results for "

Drug-resistant

" in MedChemExpress (MCE) Product Catalog:
Products (357)

357 Results for "Drug-resistant" in MCE Product Catalog:

64
64 Publications Verification
Cat. No.: HY-135748A
Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-16566
CAS No.: 59-01-8
Synonyms: Kanamycin A
Target:  

Antibiotic Bacterial

Research Areas:  

Infection Inflammation/Immunology

Kanamycin (Kanamycin A) is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-16566A
CAS No.: 25389-94-0
Synonyms: Kanamycin A sulfate
Kanamycin (Kanamycin A) sulfate is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin sulfate shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-15417
CAS No.: 110448-33-4
Purity:  99.60%
ML-7 hydrochloride is a selective and highly specific myosin light chain kinase (MLCK) inhibitor that acts as a trabecular meshwork (TM) relaxant. ML-7 hydrochloride enhances Quinocetone (HY-123581)-induced phosphorylation of ERK, p38 MAPK and JNK, attenuates Akt activation, and promotes apoptosis of hepatocellular carcinoma cells. ML-7 hydrochloride reduces Th2 cytokine secretion by inhibiting MLCK, while alleviating smooth muscle hyperplasia and collagen deposition . As a non-antibiotic adjuvant, ML-7 hydrochloride restores the sensitivity of drug-resistant bacteria to Tigecycline (HY-B0117) . ML-7 hydrochloride can be used in research related to glaucoma, hepatocellular carcinoma, asthma, and Klebsiella pneumoniae infection .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-W016420
CAS No.: 26016-99-9
Synonyms: MK-0955 sodium
Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-B1075
CAS No.: 26016-98-8
Synonyms: MK-​0955 calcium
Target:  

Bacterial Antibiotic

Research Areas:  

Infection Cancer

Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-B0609
CAS No.: 78964-85-9
Synonyms: MK-0955 tromethamine
Target:  

Bacterial Antibiotic

Research Areas:  

Infection Cancer

Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-10844
CAS No.: 187235-37-6
Purity:  99.97%
Synonyms: PA-824; (S)-PA 824
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-A0256
CAS No.: 58001-44-8
Clavulanic acid is a naturally occurring powerful bacterial β-lactamases inhibitor for research of infections caused by bacteria, including infections of the ears. Clavulanic acid is active against a wide spectrum of gram-positive and gram-negative bacterias .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-D1063
CAS No.: 207399-07-3
IR-780 is a near-infrared fluorescent probe for in vivo imaging of tumor cells. IR-780 is transported into tumor cells via OATPs and ABCB10, with uptake dependent on glycolytic activity and plasma membrane potential. IR-780 preferentially accumulates in tumor cell mitochondria, including those of drug-resistant cancer cells, without chemical conjugation. IR-780 generates reactive oxygen species (ROS), induces hyperthermia and apoptosis, inhibits tumor growth and recurrence, and modulates HSP70 expression upon ultrasound or 808 nm laser exposure. IR-780 acts as a sonosensitizer, photodynamic and photothermal agent, and drug delivery carrier, with low acute imaging-dose toxicity and rapid vital organ clearance. IR-780 can be used for the research of cancer, such as breast cancer, lung cancer, and non-small cell lung cancer (NSCLC) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-130603
CAS No.: 2242470-43-3
Purity:  99.81%
Target:  

NF-κB Apoptosis

Research Areas:  

Cancer

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14814
CAS No.: 189279-58-1
Purity:  99.95%
Synonyms: RX-3341; WQ-3034; ABT492
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Delafloxacin (RX-3341; WQ-3034; ABT492) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14814A
CAS No.: 352458-37-8
Purity:  99.87%
Synonyms: ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-117974
CAS No.: 1467157-21-6
Purity:  99.62%
Synonyms: ETX2514
Target:  

Bacterial

Research Areas:  

Infection

Durlobactam sodium salt (ETX2514) is a broad-spectrum β-lactamase inhibitor with IC50s of 4, 14 and 190 nM for Class A KPC-2, Class C AmpC and Class D OXA-24, respectively. For the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10392
CAS No.: 168828-58-8
Purity:  99.40%
Synonyms: PNU-100480; U-100480; PF-02341272
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12930
CAS No.: 1384984-18-2
Purity:  99.50%
Synonyms: VXc-486
Target:  

Topoisomerase Bacterial

Research Areas:  

Infection

SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0402
CAS No.: 71963-77-4
Synonyms: Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224
Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-19542
CAS No.: 124753-97-5
Synonyms: C6-Cer; N-Hexanoylsphingosine
Target:  

Apoptosis

Research Areas:  

Cancer

C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-150644
CAS No.: 1223194-71-5
Purity:  99.79%
Research Areas:  

Cancer

S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .
loading...
    loading...